The US Food and Drug Administration on Friday approved Moderna's respiratory syncytial virus (RSV) vaccine for older adults—marking the first time any mRNA shot has been authorized against a disease other than COVID-19.
which can be given to newborns and infants during their first RSV season. Children up to 19 months old who remain vulnerable to severe disease in their second RSV season can also get the shot.
In the late 1960s, a vaccine was produced in which the virus was inactivated with formalin, a chemical that kills viruses. The shot was given to children in Washington, D.C., but 80% of those immunized became sick and two children died, according to a journal article published in Natu...
As part of the call, Kansas Health Institute portfolio strategist Hina Shah offered a case discussion for the group. The case study involved a 70-year-old person who received the COVID-19 booster shot and this year’s flu vaccine but declined to get a shingles...
Both recommendations received unanimous support from the 11-member ACIP voting body. The committee clarified that only people who have not already received an RSV vaccine shout get a shot. Adults aged 60 to 74 years who are not at an increased risk for severe RSV disease are no lo...
The decision is a win for Moderna, which desperately needs another revenue source amidplunging demandfor its Covid jab, its only commercially available product. The approval of Moderna's shot is based on alate-stage trialon older adults, who are more vulnerable...
[03:06.52]of AstraZeneca's shot to be more popular. [03:11.44]In the U.S., about 58,000 children younger than 5 [03:16.32]are hospitalized for RSV each year. Several hundred die. [03:23.12]After years of setbacks for RSV ...
Health officials have estimated about two cases of Guillain-Barre syndrome in every 1 million people who receive the RSV vaccine within three weeks of getting the shot. The new CDC report focused on 28 cases of the syndrome in people who were vaccinated, and all but one developed symptoms wit...
GSK's vaccine, called Arexvy, and Pfizer's vaccine, called Abrysvo, target a protein from the virus called the F protein that RSV uses to attach to human cells and infect people. The vaccine stimulates antibodies against the protein and protects against infection. GSK's sh...
Two other companies – Pfizer and Moderna – also manufacture RSV vaccines approved for adults 60 and older, and are testing their shots in younger adults. Pfizertold investorslast month it was getting ready to submit "positive" data from studies of its own shot down to age 18. ...